troglitazone has been researched along with Diabetes Mellitus, Lipoatrophic in 2 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Diabetes Mellitus, Lipoatrophic: A type of diabetes mellitus that is characterized by severe INSULIN RESISTANCE and LIPODYSTROPHY. The latter may be generalized, partial, acquired, or congenital (LIPODYSTROPHY, CONGENITAL GENERALIZED).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Rosiglitazone treatment increased the triglyceride content of the steatotic livers of A-ZIP/F-1 and ob/ob mice, but not the "lean" livers of fat-transplanted A-ZIP/F-1 mice." | 1.31 | Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. ( Arioglu, E; Chao, L; Gavrilova, O; Marcus-Samuels, B; Mason, MM; Moitra, J; Reitman, ML; Vinson, C, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ganda, OP | 1 |
| Chao, L | 1 |
| Marcus-Samuels, B | 1 |
| Mason, MM | 1 |
| Moitra, J | 1 |
| Vinson, C | 1 |
| Arioglu, E | 1 |
| Gavrilova, O | 1 |
| Reitman, ML | 1 |
2 other studies available for troglitazone and Diabetes Mellitus, Lipoatrophic
| Article | Year |
|---|---|
Lipoatrophy, lipodystrophy, and insulin resistance.
Topics: Body Composition; Chromans; Diabetes Mellitus, Lipoatrophic; Humans; Hypoglycemic Agents; Insulin Re | 2000 |
Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones.
Topics: Adipose Tissue; Animals; Blood Glucose; Chromans; Diabetes Mellitus, Lipoatrophic; Disease Models, A | 2000 |